Information Provided By:
Fly News Breaks for November 2, 2017
STE
Nov 2, 2017 | 07:20 EDT
KeyBanc analyst Matthew Mishan raised his price target for STERIS to $101 from $91 post Q2. The analyst believes there is reasonable upside in the stock as it executes against achievable expectations and moving forward there are some potential catalysts, including improving organic growth, continued margin expansion, and likely increasing M&A activity. Mishan reiterates an Overweight rating on the shares.
News For STE From the Last 2 Days
There are no results for your query STE